Advertisement

Die Immuntherapie des fortgeschrittenen Harnblasenkarzinom

  • T. Otto
  • H. Rübben
Conference paper

Zusammenfassung

8% der Harnblasenkarzinome sind zum Zeitpunkt der Erstdiagnose lokal weit fortgeschritten und weisen eine Lymphknoten- oder Fernmetastasierung auf (pT3–4/N1–4/M1). Die Prognose dieser Patienten ist bei einer Langzeit-überlebensrate von weniger als 10% ungünstig. Lokale Therapiemaßnahmen haben auf die Überlebensrate von Patienten mit lymphogen-metastasierten Harnblasenkarzinomen keinen Einfluß. Smith u. Whitmore (1981) ermittelten eine 5-Jahres-Überlebensrate nach radikaler Zystektomie und Lymph-adenektomie bei Patienten mit ausgedehnter lymphogener Metastasierung (N2–N4) von 0–5% (Tabelle 1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Dretler SP, Ragsdale BD, Leadbetter WF (1973) The value of pelvic lymphadenectomy in the surgical treatment of bladder cancer. J Urol 109: 414PubMedGoogle Scholar
  2. Huland E, Huland H, Meier TH (1990) Topische Behandlung des fortgeschrittenen Harnblasenkarzinoms mit hochdosierten rekombinanten und natürlichen Interleukin-2 (IL-2)-Präparationen. Urologe [A] 29 (Suppl): A23Google Scholar
  3. Igawa M, Okkuchi T, Ueki T, Okada K, Usui T (1990) Usefullness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662–665PubMedGoogle Scholar
  4. Khandekar JD, Elson PJ, De Wys WD, Slayton RE, Harris DT (1985) Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3: 539PubMedGoogle Scholar
  5. Laplante M, Brice MH (1973) The upper limits of hopeful application of radical cystectomy for vesical carcinoma: does nodal metastasis always indicate incurability? J Urol 109: 261PubMedGoogle Scholar
  6. Logothetis CHJ, Johnson DE, Cong C et al. (1988) Adjuvant cyclosphosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6: 1590PubMedGoogle Scholar
  7. Logothetis CHJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S (1989) Cisplatin, cyclophosphamid and doxorubicin chemotherapy for unresectable urothelial tumors: The M. D. Anderson experience. J Urol 141: 33PubMedGoogle Scholar
  8. Logothetis CJ, Dexeus FH, Fin L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8/6: 1050PubMedGoogle Scholar
  9. Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ (1991) Fluorouracil and recombinant human interferon alpha-2 a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 83/4: 285PubMedGoogle Scholar
  10. De Mulder PH, Debruyne FM, Keizer HJ,Ten Bokkel Huinick W, De Pauw M, Sylvester R (1990) Randomized phase II study of methotrexate (M), cisplatin (C) and methotrexate, cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder (meeting abstract) Eur Urol 18 (Suppl 1): 5Google Scholar
  11. Recondo E, Logothetis CJ, Hossan G, Sella A, Amato RJ, Dexeus FH, Kilbourn R (1991) Results of the phase I trial combining 13-CIS retinoic acid (13-CRA) with 5-fluoracil (5-FU), alpha-interferon 2B (alpha-IFN) (Intron) in patients (PIS) with chemotherapy refractory transitional cell carcinoma (TCC) of the bladder. Proc Am Soc Clin Oncol (ASCO), 27th Ann Mtg, May 19–21, Houston, Texas, vol 10 p 174Google Scholar
  12. Rüther U, Rupp W, Schmidt A et al. (1991) Clinical experience with recombinant alpha-2-interferon treatment in patients with advanced urothelial tumors after M-VEC polychemotherapy. Ann Hematol (Suppl) A121: 131Google Scholar
  13. Smith JA Jr,Whitmore WF Jr (1981) Regional lymph node metastasis from bladder cancer. J Urol 126: 591PubMedGoogle Scholar
  14. Sternberg CN, Yagoda A, Scher HI et al. (1986) Surgical staging and long term survival in patients with advanced transitional cell carcinoma (TCC) of the urothelium treated with M-VAC. Proc ASCO 5: 390Google Scholar
  15. Sternberg CN, Yagoda A, Scher HI et al. (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461PubMedGoogle Scholar
  16. Stoter G (1985) Chemotherapy for metastatic bladder carcinoma. World J Urol 3: 110CrossRefGoogle Scholar
  17. Wadler S, Schwartz EL, Goldman M (1989) Fluorouracil and recombinant alpha- 2a-interferon: An active regime against advanced colorectal carcinoma. J Clin Oncol 7: 1769PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • T. Otto
  • H. Rübben

There are no affiliations available

Personalised recommendations